

Cyril Fauriat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4717824/publications.pdf>

Version: 2024-02-01

48
papers

4,323
citations

201385

27
h-index

243296

44
g-index

50
all docs

50
docs citations

50
times ranked

6705
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of human NK-cell cytokine and chemokine production by target cell recognition. <i>Blood</i> , 2010, 115, 2167-2176.	0.6	711
2	Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. <i>Blood</i> , 2010, 116, 3853-3864.	0.6	654
3	Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. <i>Journal of Experimental Medicine</i> , 2011, 208, 13-21.	4.2	414
4	Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. <i>Blood</i> , 2007, 109, 323-330.	0.6	321
5	Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. <i>Blood</i> , 2010, 115, 1166-1174.	0.6	256
6	Molecular Mechanisms of Natural Killer Cell Activation. <i>Journal of Innate Immunity</i> , 2011, 3, 216-226.	1.8	194
7	ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3324-3329.	3.3	181
8	Functional Analysis of Human NK Cells by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2010, 612, 335-352.	0.4	122
9	Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A <i>KIR</i> Haplotype. <i>Journal of Immunology</i> , 2008, 181, 6010-6019.	0.4	99
10	Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. <i>Leukemia</i> , 2006, 20, 732-733.	3.3	96
11	KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. <i>Blood</i> , 2009, 114, 95-104.	0.6	93
12	The co-receptor BTLA negatively regulates human $\text{V}\alpha 9\text{V}\beta 2$ T-cell proliferation: a potential way of immune escape for lymphoma cells. <i>Blood</i> , 2013, 122, 922-931.	0.6	87
13	NK cells expressing inhibitory KIR for non-self ligands remain tolerant in HLA-matched sibling stem cell transplantation. <i>Blood</i> , 2010, 115, 2686-2694.	0.6	79
14	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2014, 5, 122.	2.2	75
15	NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1541-1552.	2.0	74
16	NK cells: innate immunity against hematological malignancies?. <i>Trends in Immunology</i> , 2004, 25, 328-333.	2.9	65
17	Activating Killer Cell Ig-Like Receptors in Health and Disease. <i>Frontiers in Immunology</i> , 2014, 5, 184.	2.2	64
18	Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. <i>Blood</i> , 2005, 106, 2186-2188.	0.6	60

#	ARTICLE	IF	CITATIONS
19	Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1307.	2.2	56
20	Reconstitution of Natural Killer Cells in HLA-Matched HSCT After Reduced-Intensity Conditioning: Impact on Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 429-439.	2.0	55
21	B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. <i>Leukemia</i> , 2014, 28, 1163-1167.	3.3	54
22	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2017, 8, 573.	2.2	47
23	Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy. <i>Journal of Clinical Immunology</i> , 2012, 32, 632-646.	2.0	42
24	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. <i>Oncotarget</i> , 2017, 6, e1307491.	2.1	37
25	Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells. <i>Frontiers in Immunology</i> , 2017, 8, 64.	2.2	35
26	Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cells: evidence for a NF- κ B-dependent survival mechanism. <i>Cell Death and Differentiation</i> , 2002, 9, 768-779.	5.0	34
27	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 49548-49563.	0.8	34
28	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	29
29	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. <i>Frontiers in Immunology</i> , 2016, 7, 94.	2.2	26
30	Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. <i>Frontiers in Immunology</i> , 2018, 9, 977.	2.2	25
31	Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2015, 6, 564.	2.2	24
32	Analysis of the KIR Repertoire in Human NK Cells by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2010, 612, 353-364.	0.4	24
33	New approaches in the immunotherapy of haematological malignancies. <i>European Journal of Haematology</i> , 2003, 70, 333-345.	1.1	23
34	JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2017, 77, 6627-6640.	0.4	23
35	AML drug resistance: c-Myc comes into play. <i>Blood</i> , 2014, 123, 3528-3530.	0.6	18
36	Natural Killer Cell-triggering Receptors in Patients with Acute Leukaemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 1683-1689.	0.6	17

#	ARTICLE	IF	CITATIONS
37	Adenanthin, a new inhibitor of thiolâ€dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. <i>Immunology</i> , 2015, 146, 173-183.	2.0	16
38	Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. <i>Cancers</i> , 2021, 13, 2673.	1.7	12
39	Immunotherapy of acute myeloid leukemia based on $\hat{3}$ T cells. <i>Oncolimmunology</i> , 2012, 1, 1614-1616.	2.1	11
40	Adhesion Molecules Involved in Stem Cell Niche Retention During Normal Haematopoiesis and in Acute Myeloid Leukaemia. <i>Frontiers in Immunology</i> , 2021, 12, 756231.	2.2	11
41	Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols. <i>Lancet Oncology</i> , The, 2004, 5, 47-55.	5.1	10
42	BTLA, a key regulator of $\hat{3}$ T-cell proliferation. <i>Oncolimmunology</i> , 2013, 2, e25853.	2.1	7
43	Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 730970.	2.2	6
44	In vivo engineering of mobilized stem cell grafts with the immunomodulatory drug FTY720 for allogeneic transplantation. <i>European Journal of Immunology</i> , 2016, 46, 1758-1769.	1.6	2
45	177-P: Maintained tolerance of NK cells expressing inhibitory KIR for non-self ligands in HLA-matched sibling stem cell transplantation. <i>Human Immunology</i> , 2009, 70, S100.	1.2	0
46	Natural killer cells in leukaemia. , 2010, , 533-541.		0
47	Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial. <i>Cytotherapy</i> , 2017, 19, S16.	0.3	0
48	NK Cells Display Poor Anti Lymphoma and AML Function At Early Times Following Allogenic HLA-Identical SCT for Leukemia and Lymphomas.. <i>Blood</i> , 2012, 120, 3045-3045.	0.6	0